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MaBACKGROUND Heart failure patients with primary prevention implantable cardioverter-deﬁbrillators (ICD) may
experience an improvement in left ventricular ejection fraction (LVEF) over time. However, it is unclear how LVEF
improvement affects subsequent risk for mortality and sudden cardiac death.
OBJECTIVES This study sought to assess changes in LVEF after ICD implantation and the implication of these
changes on subsequent mortality and ICD shocks.
METHODS We conducted a prospective cohort study of 538 patients with repeated LVEF assessments after ICD
implantation for primary prevention of sudden cardiac death. The primary endpoint was appropriate ICD shock deﬁned
as a shock for ventricular tachyarrhythmias. The secondary endpoint was all-cause mortality.
RESULTS Over a mean follow-up of 4.9 years, LVEF decreased in 13.0%, improved in 40.0%, and was unchanged in
47.0% of the patients. In the multivariate Cox models comparing patients with an improved LVEF with those with
an unchanged LVEF, the hazard ratios were 0.33 (95% conﬁdence interval: 0.18 to 0.59) for mortality and 0.29
(95% conﬁdence interval: 0.11 to 0.78) for appropriate shock. During follow-up, 25% of patients showed
an improvement in LVEF to >35% and their risk of appropriate shock decreased but was not eliminated.
CONCLUSIONS Among primary prevention ICD patients, 40.0% had an improved LVEF during follow-up and 25% had
LVEF improved to >35%. Changes in LVEF were inversely associated with all-cause mortality and appropriate shocks for
ventricular tachyarrhythmias. Inpatientswhose follow-upLVEF improved to>35%, the risk of anappropriate shock remained
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525AB BR E V I A T I O N S
AND ACRONYM S
CRT = cardiac
resynchronization therapy
ICD = implantable
cardioverter-deﬁbrillator
LVEF = left ventricular
ejection fraction
NYHA = New York Heart
iationI mplantable cardioverter-deﬁbrillators (ICD)reduce the risk of all-cause mortality and suddencardiac death in patients with severe systolic
heart failure (1–4). Left ventricular ejection fraction
(LVEF) is a key criterion in determining eligibility
for a primary prevention ICD (5). However, 25% to
40% of primary prevention ICD patients improve
their LVEF to >35% after ICD implantation (6–9), call-
ing into question whether their risk for sudden car-
diac death warrants ICD generator replacement
especially in patients who have not experienced any
appropriate ICD therapy. Additionally, it is largely
unknown if improvement in LVEF affects the subse-
quent risk for mortality and sudden cardiac death
because prior studies were limited by small sample
size and lack of repeated LVEF assessments during
follow-up (6–9).SEE PAGE 532Using data from PROSE-ICD (Prospective Ob-
servational Study of Implantable Cardioverter-
Deﬁbrillators), we sought to assess the changes in
LVEF after ICD implantation and the implications of
these changes on subsequent mortality and ICD
shocks.
METHODS
STUDY DESIGN AND POPULATION. PROSE-ICD is a
multicenter prospective study of patients with sys-
tolic heart failure eligible for a primary prevention
ICD that was conducted at 4 clinical centers in the
United States from 2003 to 2013. Patients were
extensively phenotyped and followed as previously
described (10). Brieﬂy, patients 18 to 80 years of age
referred for primary prevention ICD implantation
were enrolled if they met any of the following criteria:
1) ischemic cardiomyopathy (myocardial infarction
>40 days before implant) with an ejection fraction
of #30% and stable New York Heart Association
(NYHA) functional class I to III heart failure; 2) is-
chemic or nonischemic cardiomyopathy with an
ejection fraction #35% and NYHA functional class II
or III heart failure; or 3) ejection fraction #35%
with NYHA functional class II to IV heart failure
undergoing guideline-indicated implantation of a
cardiac resynchronization therapy device with an
ICD (CRT-D). All centers obtained approval from
their respective institutional review boards and all
patients provided informed consent.
Among the 1,189 participants enrolled in the
PROSE-ICD study, 538 had their LVEF reassessed at
least once during follow-up and were selected for
the current analysis. Patients without follow-upLVEF measurements were older (62.0 vs.
58.9 years), and were more likely to be male
(75.3% vs. 70.1%) and to have higher baseline
LVEF (22.6% vs. 21.8%), ischemic cardiomy-
opathy (59.3% vs. 47.6%), and more comor-
bidities including diabetes, hypertension, or
chronic kidney disease compared with pa-
tients with follow-up LVEF measurements
(Online Table 1).
At enrollment and before ICD implantation,
all patients underwent a comprehensive medical
history and cardiovascular examination including a
digitally recorded resting 12-lead electrocardiogram,
fasting blood collection, and evaluation of LVEF. The
medical history included data on NYHA functional
class, angina class, atrial ﬁbrillation, smoking, comor-
bidities, and medication use. Estimated glomerular
ﬁltration rate was calculated using the Chronic Kidney
Disease Epidemiology Collaboration equation and
chronic kidney disease was deﬁned as an estimated
glomerular ﬁltration rate <60 ml/min/1.73 m2.
Echocardiography was the main method for esti-
mating the LVEF, accounting for 80.6% of all mea-
surements at baseline and during study follow-up.
Other methods included ventriculography (8.5%),
nuclear scintigraphy (5.1%), stress test (3.7%), com-
puted tomography scan (1.9%), and cardiac magnetic
resonance imaging (0.2%).
Patients were evaluated every 6 months after ICD
implantation either in person or by telephone and
soon after any patient-perceived ICD therapy. The
2 study endpoints were ﬁrst appropriate ICD shock
and death. An appropriate ICD shock was deﬁned
as an ICD shock for ventricular tachyarrhythmias.
Arrhythmic events were adjudicated by 2 clinical
cardiac electrophysiologists blinded to patient de-
mographic information. Disagreements were recon-
ciled by a third electrophysiologist. Deaths were
ascertained by telephone contact with the next of
kin and by searches of the National Death Index.
STATISTICAL ANALYSES. Cox proportional hazards
models were used to estimate the association of
changes in LVEF during follow-up with all-cause
mortality and appropriate shocks. All models were
stratiﬁed by enrollment center, allowing the baseline
hazard functions to differ for the centers. To describe
the changes in LVEF, we calculated the absolute
change in LVEF as the difference between the last
available LVEF measurement (for analyses of mortal-
ity) or the last LVEF measurement before the ﬁrst
appropriate shock (for analyses of appropriate shocks)
minus the baseline LVEF. For survival analysis, follow-
up time started at the time of the last available LVEF
measurement and continued through March 18, 2015.
Assoc
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526Two alternative model speciﬁcations were used
to provide detailed dose–response analyses of the
relationship between magnitude of changes in LVEF
and study endpoints. First, we categorized patients
into 3 groups: 1) worsened LVEF (absolute decrease in
LVEF >5%); 2) unchanged LVEF (absolute change in
LVEF -5% to 5%); and 3) improved LVEF (absolute
increase in LVEF >5%). Second, we introduced abso-
lute change in LVEF as restricted quadratic splines
with knots at the 5th, 50th, and 95th percentiles of
its distribution in the Cox models to allow for aTABLE 1 Baseline Characteristics
Overall
(n ¼ 538)
Worsened L
(n ¼ 70)
Age, yrs 58.9  12.2 62.5  13
Sex
Male 377 (70.1) 53 (75.7)
Female 161 (29.9) 17 (24.3)
Race
White 309 (57.4) 44 (62.9
Black 212 (39.4) 25 (35.7)
Other 17 (3.2) 1 (1.4)
Body mass index, kg/m2 30.0  6.6 30.3  7.
Smoking
Never 189 (35.1) 28 (40.0
Former 249 (46.3) 30 (42.9
Current 100 (18.6) 12 (17.1)
Baseline LVEF, % 21.8  7.2 27.3  5.
NYHA functional class
Class I 88 (16.4) 7 (10.0
Class II 245 (45.5) 38 (54.3)
Class III 202 (37.5) 24 (34.3)
Class IV 3 (0.6) 1 (1.4)
Cardiomyopathy
Nonischemic 282 (52.4) 29 (41.4)
Ischemic 256 (47.6) 41 (58.6
QRS duration, ms 120.6  31.7 120.1  29
Atrial ﬁbrillation 132 (24.5) 20 (28.6
Diabetes 164 (30.5) 25 (35.7)
Hypertension 303 (56.3) 41 (58.6
Chronic kidney disease 136 (25.3) 23 (32.9
Medications
Aspirin 343 (63.8) 49 (70.0
ACE-I/ARB 380 (70.6) 54 (77.1)
Beta-blocker 482 (89.6) 62 (88.6
Thiazide/loop diuretics 385 (71.6) 48 (68.6
Aldosterone antagonist 138 (25.7) 13 (18.6)
Device type
ICD 353 (65.6) 51 (72.9)
CRT-D 185 (34.4) 19 (27.1)
Lowest device cutoff rate, bpm 188.2  14.1 186.6  15
ATP zone used 316 (58.7) 39 (55.7)
Values are mean  SD or n (%). *p values represent the comparison across the 3 gro
LVEF -5% to 5%), and improved LVEF (absolute increase in LVEF >5%).
ACE-I ¼ angiotensin-converting enzyme inhibitor; ARB ¼ angiotensin receptor blocker;
deﬁbrillator capacity; ICD ¼ implantable cardioverter-deﬁbrillator; LVEF ¼ left ventriculsmooth yet ﬂexible description of the relationship
between change in LVEF and endpoints. For the
analysis of all-cause mortality, data from all 538 pa-
tients were used, whereas the analysis of appropriate
shocks was restricted to the 464 patients with LVEF
reassessed at least once before the ﬁrst appropriate
shock (for those who experienced an appropriate
shock) or before the study’s end (for those who did
not have an appropriate shock).
For all analyses, we used 2 models with progres-
sive degrees of adjustment. The initial model wasVEF Unchanged LVEF
(n ¼ 253)
Improved LVEF
(n ¼ 215) p Value*
.2 58.6  11.9 58.1  12.1 0.03
0.21
182 (71.9) 142 (66.0)
71 (28.1) 73 (34.0)
0.48
) 136 (53.8) 129 (60.0)
107 (42.3) 80 (37.2)
10 (4.0) 6 (2.8)
5 30.6  6.4 29.3  6.6 0.10
0.55
) 94 (37.2) 67 (31.2)
) 111 (43.9) 108 (50.2)
48 (19.0) 40 (18.6)
6 21.6  7.0 20.3  7.1 <0.001
0.36
) 44 (17.4) 37 (17.2)
114 (45.1) 93 (43.3)
95 (37.5) 83 (38.6)
0 (0.0) 2 (0.9)
0.003
122 (48.2) 131 (60.9)
) 131 (51.8) 84 (39.1)
.4 119.2  31.6 122.3  32.6 0.58
) 56 (22.1) 56 (26.0) 0.43
89 (35.2) 50 (23.3) 0.01
) 148 (58.5) 114 (53.0) 0.45
) 68 (26.9) 45 (20.9) 0.20
) 161 (63.6) 133 (61.9) 0.47
178 (70.4) 148 (68.8) 0.41
) 224 (88.5) 196 (91.2) 0.62
) 194 (76.7) 143 (66.5) 0.04
77 (30.4) 48 (22.3) 0.05
0.002
180 (71.1) 122 (56.7)
73 (28.9) 93 (43.3)
.5 187.2  13.1 189.8  14.6 0.08
164 (64.8) 113 (52.6) 0.03
ups of worsened (absolute decrease in LVEF >5%), unchanged (absolute change in
ATP ¼ antitachycardia pacing; CRT-D ¼ cardiac resynchronization therapy device with
ar ejection fraction; NYHA ¼ New York Heart Association.
TABLE 2 Changes in LVEF During Follow-Up
Overall
(n ¼ 538)
ICD Patients
(n ¼ 353)
CRT-D Patients
(n ¼ 185)
Changes in LVEF*
Worsened 70 (13.0) 51 (14.5) 19 (10.3)
Unchanged 253 (47.0) 180 (51.0) 73 (39.5)
Improved 215 (40.0) 122 (34.6) 93 (50.3)
Absolute LVEF, %
Baseline LVEF 21.8  7.2 22.4  6.9 20.6  7.5
Last LVEF 28.6  13.7 27.3  12.5 30.9  15.6
Average difference 6.7 4.9 10.2
Values are n (%) or mean  SD. *Changes in LVEF were categorized as follows: worsened ¼ absolute decrease in
LVEF >5%; unchanged ¼ absolute change in LVEF -5% to 5%; and improved ¼ absolute increase in LVEF >5%.
Abbreviations as in Table 1.
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527adjusted for baseline age, sex, race, and baseline
LVEF. The second model was further adjusted for
baseline smoking status, body mass index, NYHA
functional class, ischemic cardiomyopathy, atrial
ﬁbrillation, diabetes, hypertension, chronic kidney
disease, and device type. Additional adjustment of
the model for device characteristics (lowest cut-off
rate, antitachycardia pacing zone used) and medica-
tion use (aspirin, angiotensin-converting enzyme
inhibitors or angiotensin receptor blockers, beta-
blocker, diuretics, and aldosterone antagonist) yiel-
ded similar results (data not shown). The proportional
hazards assumption was checked by plotting the
log(-log[survival]) against log(time) and by using the
Schoenfeld residuals.
In addition to evaluating the association between
absolute changes in LVEF and mortality, we evalu-
ated the annual rate of change in LVEF, with similar
ﬁndings (not shown). We also performed separate
stratiﬁed analyses in pre-speciﬁed subgroups deﬁned
by device type (ICD, CRT-D). The signiﬁcance of
interaction term was evaluated using Wald tests.
Sensitivity analysis only including LVEF measure-
ments by echocardiogram was also performed.
All analyses were performed using STATA version
12 (StataCorp LP, College Station, Texas).
RESULTS
The average age of study participants at baseline
was 58.9  12.2 years (Table 1). Men comprised
70.1% of all subjects and 57.4% were white. During
follow-up, LVEF measures were reduced in 70
(13.0%), unchanged in 253 (47.0%), and improved in
215 (40.0%) patients (Table 2, Central Illustration). The
mean duration between the ﬁrst and last available
LVEF measurements was 4.9 years. Patients with a
worsened LVEF were more likely to be older and
have higher baseline LVEF, ischemic cardiomyopa-
thy, and diabetes compared with patients whose
LVEFs were unchanged or improved. Patients with an
improved LVEF were more likely to have a CRT-D
device (as opposed to an ICD) compared with the
rest of the population.
The mean follow-up time for endpoints since the
last available LVEF measurement was 2.0 years dur-
ing which 96 patients died and 27 experienced an
appropriate shock. In multivariate Cox models, the
hazard ratio for mortality was 0.33 (95% conﬁdence
interval: 0.18 to 0.59) comparing patients with
an improved LVEF with those with an unchanged
LVEF (Table 3). Similarly, the corresponding hazard
ratio for appropriate shock was 0.29 (95% conﬁdence
interval: 0.11 to 0.78). Spline regression analysesalso showed a consistent inverse relationship be-
tween changes in follow-up LVEF and endpoints
(Central Illustration).
Among all 538 patients, 404 (75%) had an LVEF
that remained #35%, 99 (18%) improved to 36%
to 54%, and 35 (7%) improved to $55% (Central
Illustration). Among the 464 patients who had their
LVEF reassessed at least once before the ﬁrst appro-
priate shock or who had not yet received an appro-
priate shock during follow-up, 91 (20%) had an LVEF
improved to 36% to 54%, and 35 (8%) to $55%
(Table 4). Among those whose LVEF improved to
>35%, only 4 patients experienced an appropriate
shock. Patients with CRT-D devices were more likely
to experience improvement and normalization of
LVEF compared with ICD patients (36.7% vs. 21.8%).
When the analysis was stratiﬁed by device type,
the association between changes in LVEF and out-
comes seemed to be similar in ICD and CRT-D
patients (p value for interactions ¼ 0.99 for analysis
of all-cause mortality and 0.28 for analysis of appro-
priate shock). Additionally, similar results were found
when repeating the analyses using LVEF measure-
ments by echocardiogram only (Online Figure 1).
DISCUSSION
In a prospective cohort of patients undergoing
primary prevention deﬁbrillator implantation, LVEF
worsened in 13%, improved in 40%, and was un-
changed in 47% of the patients during a mean follow-
up of 4.9 years post-implantation (Central Illustration).
Changes in LVEF during follow-up were inversely
related to all-cause mortality and appropriate ICD
shock with an improved LVEF associated with
reduced risk of death and appropriate shocks. Dur-
ing follow-up, 25% of the patients had LVEFs that
CENTRAL ILLUSTRATION Follow-Up LVEF After Primary Prevention ICD Implantation
Prospective cohort study of 538 patients with repeated left ventricular ejection fraction (LVEF) assessments after implantable cardioverter-deﬁbrillators (ICD) had
been inserted for primary prevention. (A) Patients implanted with a cardiac resynchronization therapy device with deﬁbrillator capacity (CRT-D) exhibited the
greatest improvement both in terms of absolute increase in LVEF (top panels) and the percentage improved to $35% (bottom panels). (B) Changes in LVEF
were inversely associated with all-cause mortality and appropriate shock for ventricular tachyarrhythmia. The curves represent adjusted hazard ratios and their
95% conﬁdence intervals (dashed lines) based on restricted quadratic splines for absolute change in LVEF with knots at the 5th, 50th, and 95th percentiles
of its distribution. The reference values (diamond) were set at 0% change in LVEF. Results were obtained from Cox regression models adjusted for age,
sex, race, baseline LVEF, smoking status, body mass index, New York Heart Association functional class, ischemic cardiomyopathy, atrial ﬁbrillation, diabetes,
hypertension, chronic kidney disease, device type, and stratiﬁed by enrollment center. Histograms represent the frequency distributions of the absolute change
in LVEF. Improved LVEF ¼ absolute increase in LVEF >5%; Unchanged LVEF ¼ absolute change in LVEF -5% to 5%; Worsened LVEF ¼ absolute decrease in
LVEF >5%.
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was decreased but not eliminated in these patients.
Heart failure patients may experience LVEF im-
provement as a result of medical therapies or the
correction of reversible factors that caused the car-
diomyopathy. LVEF recovery has been shown inclinical trials of heart failure therapies, such as va-
sodilators (11), angiotensin-converting enzyme in-
hibitors (12), beta-blockers (13), and CRT (14,15).
Population and community-based studies have also
demonstrated LVEF improvement in a substantial
proportion of heart failure patients. The Oregon
TABLE 3 Mortality and Appropriate Shock
All-Cause Mortality Appropriate Shock
Events/Total
Number
Incidence
Rate*
Model 1†
HR (95% CI)
Model 2‡
HR (95% CI)
Events/Total
Number
Incidence
Rate*
Model 1†
HR (95% CI)
Model 2‡
HR (95% CI)
Changes in LVEF§
Worsened 20/70 20.0 1.48 (0.84–2.61) 1.54 (0.87–2.75) 1/48 2.3 0.41 (0.04–3.73) 0.51 (0.05–5.30)
Unchanged 59/253 11.7 Reference Reference 20/219 6.9 Reference Reference
Improved 17/215 3.8 0.31 (0.18–0.54) 0.33 (0.18–0.59) 6/197 2.2 0.33 (0.13–0.85) 0.29 (0.11–0.78)
*Incidence rate calculated as per 100 person-years. †Model 1: Adjusted for age, sex, race, baseline LVEF, and stratiﬁed by enrollment center. ‡Model 2: Further adjusted
for smoking status, body mass index, NYHA functional class, ischemic cardiomyopathy, atrial ﬁbrillation, diabetes, hypertension, chronic kidney disease, and device type.
§Changes in LVEF were categorized into 3 groups: worsened LVEF (absolute decrease in LVEF >5%), unchanged LVEF (absolute change in LVEF -5% to 5%), and improved
LVEF (absolute increase in LVEF >5%).
CI ¼ conﬁdence interval; HR ¼ hazard ratio; LVEF ¼ left ventricular ejection fraction.
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529Sudden Cardiac Death Study found that among
patients with severe left ventricular dysfunction
(LVEF #35%), about one-third had an improved (36%
to 54%) or normalized ($55%) LVEF during a mean
follow-up of 2 years (16). In another large cohort of
3,994 outpatient heart failure patients, 28.6% had a
>10% improvement in LVEF, resulting in an average
increase in LVEF from 25.8% to 32.3% at 24 months
(17). Our analysis of primary prevention ICD patients
found that 40% had an improved LVEF after im-
plantation. Individuals with an improved LVEF were
more likely to be younger, have a lower baseline LVEF
and nonischemic cardiomyopathy, and were less
likely to have diabetes. This, too, aligns with prior
reports (17–19).
Few studies have evaluated the association be-
tween changes in LVEF and subsequent risk of mor-
tality and ICD therapy. In a study of 187 nonischemic
cardiomyopathy patients with LVEF <36% at base-
line, patients with an improved LVEF (increased >5%)
exhibited improved survival and a nonsigniﬁcant
decrease in the risk of appropriate shocks compared
with patients with stable (absolute change #5%) or
decreased (<-5%) LVEF (8). In another study of 91
patients (99% male) with primary prevention ICDs,
27% had improved LVEF at generator replacement;
however, the incidence rates of appropriate shockTABLE 4 Incidence Rate of Appropriate Shock by Last LVEF Measure
Last LVEF Measurement*
Overall (n ¼ 464)
n (%) Events Incidence Rate† n (%
#35% 338 (73) 23 5.5 233 (7
36%–54% 91 (20) 3 2.4 49 (1
$55% 35 (8) 1 1.7 16 (5
*Before appropriate shock. †Incidence rate calculated as per 100 person-years.
Abbreviations as in Table 1.were similar between patients with improved LVEF
and unchanged LVEF (6). Of note, among the 16
patients with improved LVEF and no ICD therapy
before generator replacement, 3 (19%) had their ﬁrst
appropriate ICD therapy after generator replacement
(6). With a larger and more inclusive primary pre-
vention ICD cohort (29.9% female and 39.4% black
patients), we found that changes in LVEF measure-
ments during follow-up were inversely associated
with all-cause mortality and appropriate shocks
and the associations were similar among ICD and
CRT-D patients. Although our study represents a
large cohort of primary prevention ICD patients with
follow-up LVEF measurements, only 27 patients
experienced an appropriate shock among those with
a follow-up LVEF measurement before the ﬁrst
appropriate shock. This is likely because patients
were more likely to have their LVEF reassessed after,
but not before, ICD shocks.
LVEF improvement to >35% was observed in 25%
of our study population, and these patients seemed
to have a lower incidence of appropriate shocks
compared with patients whose LVEF remained #35%.
This was consistent with previous smaller studies
that found a reduction, but not elimination, of the
risk of appropriate ICD shock after LVEF improved
to >35%. In a registry-based study of 157 patientsment Before Appropriate Shock
ICD Patients (n ¼ 298) CRT-D Patients (n ¼ 166)
) Events Incidence Rate† n (%) Events Incidence Rate†
8) 13 4.8 105 (63) 10 6.8
6) 2 3.5 42 (25) 1 1.5
) 0 0 19 (11) 1 2.6
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530with idiopathic dilated cardiomyopathy and primary
prevention ICDs, 33.8% demonstrated an improve-
ment in follow-up LVEF to >35% during a mean of
26 months and their incidence of appropriate ICD
therapy was lower compared with patients whose
LVEF did not improve to >35% (10 events in 53
patients who had such an improvement in LVEF
vs. 34 events out of 104 patients who did not
show such LVEF improvement) (7). In the DEFINITE
(Deﬁbrillators in Non-Ischemic Cardiomyopathy
Treatment Evaluation) trial, 37% of patients had a
follow-up LVEF >35% during the ﬁrst 2 years and
they experienced a signiﬁcantly lower incidence of
arrhythmic events compared with patients whose
LVEF remained #35% (4 of 70 vs. 24 of 117 events)
(8). Similarly, a recent retrospective chart review of
231 patients with primary prevention ICDs found
that 26% of the patients had LVEF improved
to $40% with no prior appropriate ICD therapy.
When these patients were followed over time, they
received signiﬁcantly fewer ICD therapies (9).
Lastly, a retrospective study of 423 patients with
CRT-D also found that post-implantation LVEF was
inversely associated with the risk of subsequent
appropriate ICD therapy and the 2-year risk of
appropriate therapy was <3.3% in patients whose
LVEF had improved to $45% (18). The observation
that risk of arrhythmic events persists despite im-
provement in LVEF may be partly explained by the
presence of a ﬁxed substrate for ventricular ar-
rhythmias (e.g., ﬁbrosis, myocardial scar, heteroge-
neous repolarization) that does not resolve even
when LVEF improves, suggesting that improve-
ments in LVEF alone may not be enough to warrant
deferring ICD generator exchange (8).
STUDY LIMITATIONS. This analysis was restricted to
patients with repeated LVEF assessment after ICD
implantation. Compared with patients included in
our analysis, those who were excluded because of a
lack of follow-up LVEF measurement were on average
older, had a higher baseline LVEF, a higher preva-
lence of ischemic cardiomyopathy, higher burden of
comorbidities, and a higher risk of mortality. Because
excluded patients had higher baseline LVEF and,
thus, were more likely to have a worsened or un-
changed LVEF, yet also higher mortality, the poten-
tial bias resulting from these exclusions was likely
toward the null. In addition, LVEF was measured by
different modalities including echocardiography,
ventriculography, nuclear scintigraphy, computed
tomography, and cardiac magnetic resonance. Some
evidence suggests that LVEF measured by differentmethods may differ from each other (20). However,
when restricting the analysis to only include LVEF
measurements by echocardiography, we found very
similar results. The mode of death could not be
established in many patients because of the lack of
reliable records when patients died out of hospital.
As a consequence, we could not examine the asso-
ciation between LVEF changes and cause-speciﬁc
mortality. Lastly, we were not able to assess if
changes in device programming during follow-up
may impact our ﬁndings because this information
was not available in our study. However, adjustment
for device characteristics at baseline virtually did not
change the results.
CONCLUSIONS
In a prospective cohort of patients undergoing pri-
mary prevention ICD implantation, 40% of the pa-
tients showed an improved LVEF during follow-up; in
25%, LVEF improved to >35%. Changes in LVEF were
inversely associated with the risk of all-cause mor-
tality and appropriate shocks. In patients whose
follow-up LVEF improved to >35%, the risk of
an appropriate shock was markedly decreased but
still present, suggesting that improvements in ejec-
tion fraction alone may not be enough to warrant
deferring ICD generator exchange.
Findings from our study indicate that repeated
LVEF assessments after ICD implantation can provide
additional prognostic information and may also allow
for more informed decision making regarding ICD
generator replacement, especially in patients whose
LVEF improved signiﬁcantly. Further studies in larger
populations with more frequent and prospectively
determined LVEF reassessments are needed to better
understand how changes in LVEF after ICD implan-
tation modulate the risk of mortality and appropriate
shocks. More studies are also needed to provide
greater guidance on which patients with LVEF im-
provement should actually defer generator exchange.
Randomized clinical trials of generator replacement
in patients whose LVEF improved to >35% are
necessary to provide the most convincing evidence
as to whether ICD generator replacement has a posi-
tive or negative impact in this particular patient
population.
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PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: In a
prospective cohort study of patients with repeated
assessments of LVEF after ICD implantation for primary
prevention of lethal ventricular arrhythmias, 40%
exhibited improvement in ejection fraction during a mean
follow-up of 4.9 years, with LVEF exceeding 35% in 25%
of patients. Changes in LVEF were inversely associated
with all-cause mortality and appropriate shocks for
termination of ventricular tachyarrhythmias.
TRANSLATIONAL OUTLOOK: Further studies are
needed to discover the mechanisms linking changes
in LVEF after ICD implantation to the risks of
ventricular tachyarrhythmias and mortality, and
to determine whether patients in whom ejection
fraction improves might safely defer generator
replacement.
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